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Arginase 1+ microglia reduce Aβ plaque
deposition during IL-1β-dependent
neuroinflammation
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Abstract
Background: Neuroinflammation has long been considered a driver of Alzheimer’s disease progression. However,
experiments developed to explore the interaction between neuroinflammation and Alzheimer’s disease (AD)
pathology showed a surprising reduction in amyloid beta (Aβ) plaque deposition. We sought to understand this
unexpected outcome by examining microglia phenotypes during chronic neuroinflammation.
Methods: Using an adeno-associated virus vector carrying hIL-1β cDNA, inflammation was induced in one
hippocampus of 8-month-old amyloid precursor protein (APP)/PS1 mice for 4 weeks, while the other hemisphere
received control injections. Bone marrow chimeras and staining analysis were used to identify the origins and types
of immune cells present during sustained inflammation. Arginase 1 (Arg1) and inducible nitric oxide synthase
(iNOS) immunoreactivity were used as markers of alternatively activated and classically activated cells, respectively,
and changes in cellular uptake of Aβ by Arg1+ or iNOS+ microglia was demonstrated by confocal microscopy. To
determine if an anti-inflammatory phenotype was present during neuroinflammation, RNA was extracted on
flow-sorted microglia and rt-PCR was performed. Interleukin-4 injection was used to induce alternatively activated
cells, whereas a minipump and intrahippocampal cannula was used to deliver an interleukin (IL)-4Rα antibody to
block the induction of Arg1+ cells in the setting of sustained IL-1β expression.
Results: We observed a robust upregulation of centrally derived Arg1+ microglia present only in the inflamed
hemisphere. Furthermore, in the inflamed hemisphere, greater numbers of Arg1+ microglia contained Aβ when
compared to iNOS+ microglia. RNA isolated from flow-sorted microglia from the inflamed hemisphere
demonstrated elevation of mRNA species consistent with alternative activation as well as neuroprotective genes
such as BDNF and IGF1. To explore if Arg1+ microglia mediated plaque reduction, we induced Arg1+ microglia
with IL-4 and observed significant plaque clearance. Moreover, when we reduced Arg1+ microglia induction in the
context of neuroinflammation using an anti-IL-4Rα antibody delivered via intrahippocampal cannula, we observed a
clear correlation between numbers of Arg1+ microglia and plaque reduction.
Conclusions: Together, these findings suggest that Arg1+ microglia are involved in Aβ plaque reduction during
sustained, IL-1β-dependent neuroinflammation, opening up possible new avenues for immunomodulatory therapy
of AD.
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Background
Microglia are now recognized as critical regulators of
brain immunity and homeostasis and are therefore
likely to play important roles in neurological disorders
such as Alzheimer’s disease (AD), which is character-
ized by the presence of chronic neuroinflammation
and accumulation of the pathological protein amyloid
beta (Aβ) [1]. The link between these two compo-
nents has given rise to a concept known as the in-
flammatory cascade hypothesis. This hypothesis states
that Aβ-induced neuroinflammation can increase Aβ
production, which can further increase neuroinflam-
mation, leading to a vicious cycle that promotes AD
pathogenesis [2]. In order to test this idea, we previ-
ously developed a model to explore the production of
the proinflammatory cytokine interleukin (IL)-1β in
the context of the APPswe/PSEN1dE9 (amyloid pre-
cursor protein (APP)/PS1) AD mouse. After 1 month
of sustained IL-1β-induced inflammation, we surpris-
ingly observed reduced Aβ deposition [3], which we
later showed to be independent of the timing or dur-
ation of IL-1β induction and were able to demon-
strate in a second AD mouse model [4, 5]. In this
context, we described elevated microglial activity and
recruitment around Aβ plaques, suggesting that these
cells might contribute to decreased pathology [3–5].
Interestingly, other groups have reported similar find-
ings in AD mice using different inflammatory cyto-
kines, indicating that this result may be a more
fundamental effect of neuroinflammation [6, 7].
Many questions still remain as to how microglia exert
this seemingly beneficial effect in the context of a strong
neuroinflammatory response. Importantly, recent work re-
veals that microglia can adopt a diverse set of “activation”
phenotypes based on different environmental cues [8] that
parallel findings originally described in peripheral macro-
phages [9]. For example, inflammatory cytokines such as
TNFα or IFNγ can polarize microglia towards a classical
activation phenotype characterized by inflammatory cyto-
kine production; whereas the anti-inflammatory cytokines
IL-4, IL-13, or IL-10 shift microglia towards an alternative
activated phenotype characterized by debris clearance and
anti-inflammatory cytokine production [8]. These two
phenotypes have been designated M1 and M2 micro-
glia, respectively [10]. The inflammatory and anti-
inflammatory properties of microglia do not appear to
be strictly limited to either M1 or M2 polarized cells;
instead, the M1 and M2 designations may rest on the
extreme ends of a spectrum of microglial phenotypes
[11]. Interestingly, recent evidence suggests a mixed
M1/M2 phenotype is more realistic [12]. However,
where the population as a whole lies on the inflam-
matory vs. anti-inflammatory spectrum can dictate
outcomes in disease [13].
In AD, the microglial phenotype has been suggested to
be a key mechanism involved in disease progression. Be-
ing the sentinel innate immune cell in the central ner-
vous system (CNS), phagocytosis of foreign/disease
substances falls under microglial jurisdiction. Thus, Aβ
accumulation suggests that microglia fail to perform a
normal function. Indeed, several studies have observed
that exposure to inflammatory cytokines inhibits micro-
glial phagocytosis of Aβ [14]. The concept that inflam-
matory microglia fail to properly respond in disease
suggests an anti-inflammatory response could potentially
be beneficial for disease outcome. It has been reported
that anti-inflammatory cytokines such as IL-4 can result
in elevated clearance of pathological proteins both in
vivo and in vitro [15, 16]. However, a detailed in vivo
study specifically showing that anti-inflammatory micro-
glia are both sufficient and necessary for clearance has
not been accomplished. Using a previously described re-
combinant adeno-associated virus serotype 2 expression
vector containing the mature form of human IL-1β
(rAAV2-IL1β) [17], we observed that inflammation re-
sults in the recruitment of cells capable of producing the
anti-inflammatory cytokine IL-4 into the brain. This re-
cruitment was accompanied by the emergence of an
Arg1+ microglia phenotype that preferentially engulfed
Aβ. Furthermore, we demonstrated that Arg1+ microglia
have the potential to be a driver of Aβ plaque reduction.
Materials and methods
Animals
All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee at the University
of Rochester, protocol 2006-161R. Heterozygous
APPswe/PS1dE9 mice (stock no. 004462) and mice with
a monomeric red fluorescent protein (mRFP) under con-
trol of the chicken beta actin promoter (stock no.
005884) were purchased from the Jackson Laboratory.
Mice were bred in-house to accrue appropriate experi-
mental numbers. APPswe/PS1dE9 and wild type C57BL/
6 mice were aged 7–8 months before injections were
performed. Mice harboring enhanced green fluorescent
protein (eGFP) under control of the interleukin-4 pro-
moter (4Get mice) (Jackson Laboratory stock no.
004190) on a Balb/c background were a generous gift
from the laboratory of Deborah Fowell.
Construction of recombinant adeno-associated virus
serotype 2
The construction and characterization of rAAV2 have
been previously described [17]. The final plasmid con-
taining a CMV promoter, ssIL-1β construct, SV40 polyA
tail, and inverted terminal repeats was used to produce
recombinant adeno-associated virus serotype 2 using a
baculovirus intermediary and S9 cells as previously
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described [18]. rAAV2-Phe-scFv was used as an irrele-
vant control viral vector; -Phe expresses a single-chain
antibody against phenobarbital [19].
Stereotactic injections
Animals received intracranial viral injections while
under isoflurane anesthesia (1.75 % isoflurane in 30/
70 % oxygen/nitrogen gas) using a Kopf stereotactic ap-
paratus. Mice were secured using ear bars and a head
holder. Ophthalmic ointment was applied to prevent
drying of the eyes. Betadine was used to disinfect the
scalp prior to incision with a scalpel. For intrahippocam-
pal injections in APP/PS1, 4Get, and wild-type mice, a
0.5-mm burr hole was drilled 2.18 mm caudal and
1.5 mm lateral from the bregma. A 33-GA needle was
lowered 2 mm over 2 min. A Micro-1 microsyringe
pump controller (World Precision Instruments) was
used to inject 5 μL of rAAV2-IL1β or rAAV2-Phe using
the convection-enhanced delivery (CED) method result-
ing in delivery of approximately 1.5 × 108 infection parti-
cles/mL into each hippocampus as previously performed
[20]. For intracortical injections into APP/PS1 mice, a
0.5-mm burr hole was drilled 1.5 mm caudal and 3 mm
lateral from the bregma. A 33-GA needle was lowered
1.8 mm. Two microliters of recombinant interleukin-4
was injected at a rate of 200 nL/min for 10 min to de-
liver a final dose of 100 ng. The contralateral hemisphere
received saline. The burr hole was filled with bone wax
(Ethicon, Somerville, NJ), and the incision closed with 5-
0 Dermalon sutures (Covidien, Mansfield, MA). Betadine
and topical lidocaine were applied to the top of the su-
ture to prevent infection and for analgesia, respectively.
Mice recovered in a heated area before being placed in
their home cage. Animals were sacrificed 1 month post-
viral injection and 5 days post-IL-4 injection.
Intrahippocampal cannulation
Forty-eight hours before the cannula was inserted into
animals, Micro-Osmotic pumps (Alzet Model 1004) and
Brain Infusion Kits (Alzet 0008851) were prepared. One
hundred microliters of Anti-IL-4Rα (BD 552288) or
Control IgG2a κ isotype (BD 55487) at a concentration
of 1 mg/mL was injected into the Alzet pump. The flow
moderator and tubing was attached as per manufac-
turer’s instructions. Pumps were placed into sterile saline
and pre-incubated at 37 °C for 48 h for priming. On the
day of surgery, animals were anesthetized and the skull
was prepared and drilled using the same protocol and
coordinates as the intrahippocampal stereotactic injec-
tions described above. Mice received 5 μL rAAV2-IL1β
in one hippocampus while the contralateral hemisphere
received 5 μL rAAV2-Phe. Immediately after viral injec-
tion and removal of the needle, the cannula was attached
to the primed Micro-Osmotic pump. Using the incision
in the skull, the Micro-Osmotic pump was gently
inserted under the skin and down the back. The cannula
was then inserted into the brain using the same burr
hole as rAAV2-IL1β. The cannula was slowly lowered to
1.5 mm then secured to the skull with dental glue (C&B
Metabond, Stock no. S380). The contralateral burr hole
was filled in with dental wax and the incision was closed
with 5-0 Dermalon sutures (Covidien, Mansfield, MA).
The Micro-Osmotic pump delivered 2.64 μg/day of anti-
IL-4Rα or control IgG antibody. Mice were sacrificed
28 days later.
Bone marrow chimera
Five-month-old C57BL/6 mice received two doses of
6 Gy total body irradiation separated by 4 h. We used a
Shepherd Irradiator (J.L. Shepherd and Associates) with
a 6000 Ci 137Cs source. Care was taken to shield the
head to avoid neuroinflammation induced by brain radi-
ation. Immediately after irradiation, mice received bone
marrow isolated from tibias and femurs of mRFP donor
mice. Each bone marrow recipient received 200 μL of
suspension for a total of 1.2 million cells via tail vein in-
jection. After an 8-week reconstitution period, mice
were subject to both rAAV2-IL1β and rAAV2-Phe hip-
pocampal injection as described above. Upon sacrifice,
blood was collected for analysis of reconstitution effi-
ciency of the donor marrow (range of 86.1–95.1 %
CD45/mRFP positive cells). Briefly, whole blood was
lysed with ACK Lysis Buffer (Invitrogen) for 5 min at
room temperature. Following lysis, cells were washed
with ×1 phosphate-buffered saline (PBS) containing 2 %
fetal bovine serum (FBS), incubated in Fc block (BioLe-
gend), and stained with CD45-APC-eFluor 780 (eBios-
ciences, 47-0451-80, 1:500) and Hoechst 33258
(Molecular Probes, H1318, 1:100). Samples were ana-
lyzed on a FACS LSRII (Becton Dickinson) in the Uni-
versity of Rochester Medical Center Flow Cytometry
Core facility, and data was acquired using FlowJo (vX)
for Mac.
Tissue
Animals were anesthetized and perfused with saline and
4 % paraformaldehyde (PFA) as previously described [5].
Harvested brains were post-fixed in 4 % PFA for 2 h at
4 °C. The fixed tissue was transferred to 30 % sucrose
until equilibrated then snap-frozen in isopentane at
−80 °C until used for immunohistochemistry (IHC).
Immunohistochemistry
Brains were sectioned at 30 μm on a sliding knife micro-
tome with a −25 °C freezing stage. Sections were stored in
cryoprotectant at −20 °C until processing. Antibody stain-
ing was visualized using immunofluorescent secondary
antibodies bound to Alexa fluorophores (Invitrogen) at a
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dilution of 1:500. Primary antibodies used were mouse
anti-6E10 (Covance, clone 6E10, 1:1000), goat anti-
Arginase 1 (Santa Cruz, sc-18354, 1:500), rabbit anti-
iNOS (Enzo, ADI-905-431-1, 1:500), rabbit anti-NeuN
(Millipore, ABN78, 1:1000), rabbit anti-GFAP (Dako,
Z0334, 1:3000), rabbit anti-Iba1 (Wako, 016–20001,
1:3000), rabbit anti-Cd11c (Thermo Scientific, PA1-46162,
1:500), rat anti-Ly-6B.2 (Serotec, clone 7/4, 1:1000), rat
anti-CD3 (BD Bioscience, clone G4.18, 1:500), and rat
anti-Lamp1 (DSHB, clone D1B4, 1:2000). For Congo red
staining, Kit HT60 from Sigma-Aldrich was used.
Quantitative Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
qRT-PCR array: 7- to 8-month-old APP/PS1 and
C57BL/6 mice were subjected to either bilateral intra-
hippocampal rAAV2-IL1β or rAAV2-Phe injection as de-
scribed above. One month after virus injection, mice
were sacrificed, the brain harvested, and hippocampi iso-
lated. A single-cell suspension was achieved using a
Neural Tissue Dissociation kit (Miltenyi Biotec, 130-
092-628). Myelin was removed using Myelin Removal
Beads II (Miltenyi Biotec, 130-096-773). Cells were
washed with ×1 PBS containing 0.5 % FBS, then incu-
bated in Fc block (BioLegend), and stained with CD45-
APC (BD Pharmingen, 557672), CD11b-Alexa Fluor 488
(BD Pharmingen, 561018), and DAPI. CD45 low, CD11b
+ microglia were sorted by running samples on a FAC-
SAria IIu (Becton Dickinson) in the University of Roch-
ester Flow Core. Figure 3a shows the gating strategy
for isolating microglia. Sorted microglia were collected
into lysis buffer. Immediately after sorting, samples
were processed to purify mRNA using the RNeasy
Mini Plus kit (Qiagen, 74134). Purified mRNA was
then amplified by using NuGen PicoSLv2 (NuGen).
Samples were run on a custom TaqMan Array Micro
Fluidic Card (Life Technologies Cat# 4342253) using a
QuantStudio 12K Flex Real-Time PCR system (Life
Technologies, Cat# 4471087). Expression values were
viewed and analyzed using ExpressionSuite Software
(Life Technologies, Version 1.0.3). To properly control
for samples that did not have detectable mRNA, an
imputation algorithm was used as previously de-
scribed [21].
Standard qRT-PCR: Virus injections and tissue col-
lection were performed as described in the qRT-PCR
array. Once the hippocampi were isolated, they were
immediately snap frozen in −70 °C isopentane. RNA was
isolated from frozen hippocampi using TRIzol (Invitrogen)
and an Omni International TH tissue homogenizer
according to the manufacture’s protocols. cDNA was pre-
pared using 1 μg of RNA and SuperScript III (Invitrogen).
qRT-PCR for IL-4 was conducted using predesigned
primer/probe sets (Applied Biosystems). For the
housekeeping gene 18S, Taqman probe/primer sets con-
structed with FAM as the fluorescent marker and Black-
hole I quencher (Biosearch Technologies) were used as
follows: from 5′ to 3′ 18S, forward primer (F), cct gga
tac cgc agc tag gaa; reverse primer (R), act aag aac ggc
cat gca cca; and probe (P), cgg cgg cgt tat tcc cat gac c.
Standard curves were generated using serial diluted
samples over at least 5 orders of magnitude. PCR reac-
tions were performed using iQsupermix (Bio-Rad) and
1 μL of cDNA. PCR conditions were as follows: denatur-
ation at 95 °C for 3 min, followed by 50 cycles of ampli-
fication by denaturing at 95 °C for 30 s, annealing at
60 °C for 30 s, and extension at 72 °C for 30 s. To deter-
mine relative differences in mRNA, reaction efficiency
(E) was calculated from a standard curve and cycle
threshold (Ct) values were transformed using the equa-
tion expression = (1 + E)Ct. For normalization, 18S ribo-
somal RNA was used as the housekeeping gene.
IHC analysis
Brain sections were viewed with an Axioplan 2i light
microscope (Zeiss). For plaque area, a ×10 lens was
used. Multiple images were taken for a single section
to obtain pictures of the cortex and hippocampus.
Images were merged together in Slidebook (v6.0.4)
and subjected to threshold analysis using the max en-
tropy algorithm in NIH Image J (V1.49m, http://
rsbweb.nih.gov/ij/). The percent area occupied by
6E10 of the cortex or hippocampus was calculated
and analyzed. The plaque ratio was generated by div-
iding the amount of plaque area in the inflamed
hemisphere by the amount of plaque area in the con-
trol hemisphere. This was performed with three hip-
pocampal sections per mouse and then averaged
together. Statistics were generated with Student’s t
test. Cell counts and co-localization were analyzed by
capturing images at ×20 magnification. Multiple im-
ages of the hippocampus were acquired and then
montaged together using Slidebook. The images were
transferred to NIH Image J and the GFP number or
arginase 1 (Arg1) cell number was counted manually
using the cell counter feature. To determine co-
localization for Aβ internalization, Arg1 cell type, per-
ipheral RFP infiltration, and GFP expression, images
were counted manually by switching individual color
channels to view areas of overlap. Confocal images
were captured using an Olympus FV100 laser scan-
ning confocal microscope (Center Valley, PA). Ana-
lysis of Aβ internalization, Arg1, and nitric oxide
synthase (iNOS) cell number was performed using
Student’s t test. Correlation between Arg1 cell num-
ber and Aβ plaque area was calculated using Pearson
correlation coefficients.
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Results
Alternatively activated microglia are induced after
sustained IL-1β production
Using a different system of sustained IL-1β expression,
we previously demonstrated increased microglia/macro-
phage activation using MHCII expression and morpho-
logical criteria [3, 4]. However, we did not characterize
specific activation phenotypes of these microglia. Arg1 is
a commonly used marker of alternatively activated
microglia and macrophages [22]. We first explored if
Arg1+ cells were present during sustained inflammation.
rAAV2-IL1β was injected into one hippocampus of
APP/PS1 mice while the contralateral hemisphere re-
ceived rAAV2-Phe, which expresses a single-chain anti-
body to phenobarbital and was used as a control viral
vector. Four weeks later, we looked for the presence of
Arg1+ cells. Figure 1 shows the presence of Arg1+ cells
only in the rAAV2-IL1β-injected hippocampus. Further-
more, some of these Arg1+ cells appeared to be associ-
ated with Aβ plaques (Fig. 1 inset).
Arg1 staining is mainly described in macrophage-like
cells; however, there have been other reports suggesting
infiltrating cells such as neutrophils can express it [23].
To confirm that the Arg1+ cells we observed were
microglia/macrophages, dual immunohistochemistry was
performed for multiple-cell markers including microglia,
astrocytes, neurons, neutrophils, dendritic cells, and T
cells (Fig. 2). We observed that Arg1 staining only over-
lapped with Iba1, indicating that microglia/macrophages
were the principal cell type expressing this activation
marker. Due to the differences in the origins and func-
tions between microglia and macrophages [24], it was
important to distinguish whether the Arg1+ cells arose
from brain-derived microglia or infiltrating peripheral
macrophages. Interestingly, we previously demonstrated
that even though macrophages accumulate in our model
of IL-1β expression, they are not involved in the ob-
served clearance of Aβ, suggesting a microglia-mediated
mechanism [20]. To establish the origin of Arg1+ cells, a
bone marrow chimera was created. Five-month-old
C57BL/6 mice received bone marrow from RFP donor
mice. During the creation of chimeric mice, we
avoided cranial radiation exposure by shielding the
head. At 7 months of age, chimeric mice received a
unilateral injection of rAAV2-IL1β and were sacrificed
1 month later. Arg1 staining was performed, and the
number of Arg1+ cells that co-stained with RFP was
counted (Additional file 1: Figure S1). Only 10.2 ±
3.4 % of Arg1+ cells co-labeled with RFP, suggesting
that the majority (~90 %) of Arg1+ cells observed
represent brain-derived microglia.
Microglia phenotype characterization
To further characterize the microglia population, multi-
gene qRT-PCR was performed. First, it was necessary to
separate microglia from macrophages. Therefore, in-
flamed hippocampi of APP/PS1 mice were dissected,
CD11b+ CD45Low microglia were isolated by flow cy-
tometry (Fig. 3a), and subjected to mRNA extraction. In
order to properly gauge the glial phenotype during in-
flammation, we chose to examine genes that could be
classified as inflammatory or anti-inflammatory. For the
inflammatory genes examined, we observed significant
elevation in murine IL-1β, IL-12b, TNFα, and toll-like
receptor (TLR)2 and a decrease in NLRP3 and TLR4
(Fig. 3b). For those genes classified as anti-inflammatory,
we observed an increase in Arg1, YM1, CCL17, IL-1Ra,
IGF1, and BDNF, while Fizz1, TGFβR1, and TREM2
showed decreased expression (Fig. 3c). Overall, it ap-
pears that relative to control-injected APP/PS1 mice, IL-
1β expression leads to an increase in markers consistent
with a mixed microglial phenotype.
Fig. 1 Arg1 microglia are induced after rAAV2-IL1β injection. Representative hippocampal images 4 weeks after rAAV2-IL1β injection. Images were
acquired from the same histological section and show that induction of Arg1+ cells (green) was limited to the inflamed hemisphere (rAAV2-IL1β).
Inset shows Arg1+ cells surrounding 6E10+ Aβ plaques (red). Sections were counterstained with DAPI (blue) to show cell nuclei. Scale bar
represents 200 μm in low-power images and 50 μm in high-power inset
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Arg1+ microglia contain Aβ in vivo
To determine whether Arg1+ cells associated with amyl-
oid plaques might be involved in the clearance of Aβ, we
examined tissues for co-localization of Arg1 and Aβ.
Indeed, we observed multiple examples of Arg1+ cells
containing Aβ (Fig. 4a). To establish whether this
association was selective for Arg1+ cells, we used iNOS
as a marker of inflammatory microglia [25] and counted
the number of each cell type that contained Aβ (via
6E10 labeling) in hippocampal sections (Fig. 4b). In the
control-injected hemisphere, we observed only iNOS+
cells containing Aβ. However, in the inflamed hippocam-
pus, we observed a nearly twofold increase in the num-
ber of Arg1+ microglia that contained Aβ compared to
iNOS+ microglia. To confirm that these microglia were
engulfing and shuttling Aβ to the lysosome, we stained
Fig. 2 Arg1-positive cells co-localize with microglia/macrophage markers. Representative images of multiple cell types found in the brain during
sustained IL-1β-induced neuroinflammation. Arg1+ cells only co-localize with Iba1. Scale bar represents 100 μm
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tissue sections with Lamp1 to examine lysosome co-
location. We found that both iNOS+ and Arg1+ micro-
glia contained Aβ in lysosomal compartments (Fig. 4c).
IL-4-producing cells are present during inflammation
Alternative microglia induction is thought to be
dependent on anti-inflammatory cytokines such as IL-4
or IL-13 [26, 27]. Therefore, we utilized an IL-4 GFP re-
porter mouse (4Get) to determine whether IL-4-
producing cells were present in the brain after sustained
IL-1β inflammation. 4Get mice were injected unilaterally
with rAAV2-IL1β and sacrificed 1 month later. As
shown in Fig. 5a, GFP+ cells were readily apparent in
the inflamed hemisphere, while the control hemisphere
was devoid of such cells. We next determined the iden-
tity of these cells using dual immunofluorescence stain-
ing with cell-specific antibodies. These results suggested
that multiple cell types were capable of expressing IL-4
in our model. Of the cells that labeled with GFP, 28.7 ±
4.2 % were CD3+ T cells, 17.9 ± 5.6 % were 7/4+ neutro-
phils, 12.1 ± 1.9 % were GFAP+ astrocytes, and 12.1 ±
2.6 % were Iba1+ microglia (average ± SEM). To confirm
the results seen in the 4Get mice and extend them to
the APP/PS1 model, qRT-PCT was performed on iso-
lated hippocampi from 9-month-old APP/PS1 mice
injected with rAAV2-Phe or rAAV2-IL1β. As shown in
Fig. 5b, a significant increase in IL-4 mRNA is observed
1 month after rAAV2-IL1β injection. This suggests that
cells capable of producing IL-4 are present in our AD
mouse model during sustained inflammation.
Arg1+ microglia can clear Aβ
rAAV2-IL1β-induced inflammation has diverse effects on
many cell types in the CNS [17]. In order to prove that
Arg1+ microglia were a critical cell type involved in plaque
reduction, we sought to specifically induce them independ-
ent from chronic inflammation. Based on our observation
of IL-4-producing cells (Fig. 5) and their common use to
specifically induce an alternate macrophage phenotype
[28], we injected 100 ng of IL-4 into the cortex of APP/PS1
mice and an equal volume of saline into the contralateral
hemisphere. Five days later, we sacrificed the mice and
stained tissues for Aβ using 6E10. Figure 6a depicts clear
induction of Arg1+ cells in the IL-4-treated cortex.
Fig. 3 Microglial phenotype genetic profile. a Representative image
demonstrating the gating strategy used to isolate CD11b+ CD45low
microglia. Circled area represents sorted microglia population. qRT-PCR
analysis of inflammatory (b) and anti-inflammatory (c) gene expression
for hippocampal CD11b+ CD45low microglia during sustained
inflammation. Values are normalized to the control, rAAV2-Phe-injected
hemisphere, represented by the dotted line. Data was analyzed with
Student’s t test. Data displayed as mean ± SEM, n = 4–5 animals.
*p < 0.05, **p < 0.005, ***p < 0.0001
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Quantification of Aβ plaque load demonstrated a reduction
in the IL-4-treated cortex compared to the saline-injected
hemisphere (Fig. 6b), suggesting that IL-4-induced Arg1+
microglia have the capacity to clear amyloid plaques.
Arg1+ microglia are involved in plaque reduction
Previous studies in macrophages demonstrated that IL-
4-signaling inhibition impairs Arg1+ polarization [26].
Our results suggest that Arg1+ mice are necessary for
IL-1β-induced plaque reduction. Therefore, to directly
test this hypothesis, an osmotic minipump system was
used to chronically deliver an anti-IL-4Rα antibody in
APP/PS1 mice with sustained IL-1β expression. Mini-
pumps were loaded with 100 μL anti-IL-4Rα and con-
nected to an intrahippocampal cannula. Immediately
after rAAV2-IL1β injection, cannulas were implanted
0.5 mm above the injection site in APP/PS1 mice. The
contralateral hemisphere received rAAV2-Phe. A control
set of APP/PS1 mice received the same rAAV2-IL1β
injections, but the minipump contained an equivalent
amount of control IgG. After 1 month, mice were
sacrificed and brain tissues analyzed for the presence
of Arg1+ cells and amyloid plaque load. We observed
that IL-4Rα antibody treatment successfully reduced
the numbers of Arg1+ cells in the inflamed hemi-
sphere (Fig. 7a, c). Moreover, we observed that anti-
IL-4Rα treatment attenuated the reduction of Aβ
plaque load seen in rAAV2-IL1β-injected mice (Fig. 7b,
e). To verify that only the anti-inflammatory response
was affected, we counted the number of inflammatory
microglia and found that anti-IL-4Rα treatment did
not significantly alter the numbers of iNOS+ cells
(Fig. 7d). Finally, we observed a significant negative
correlation between numbers of Arg1+ cells and Aβ pla-
ques across the inflamed hippocampi of all mice used in
this experiment (Fig. 7f). Together, these results suggest




Fig. 4 Aβ is taken up by Arg1+ microglia. a Representative confocal images of Arg1+ cell (green) containing Aβ (red) after rAAV2-IL1β injection.
DAPI (blue) is used as to counter stain cell nuclei. Scale bars represent 10 μm. b Quantification of iNOS+ or Arg1+ microglia in the hippocampus
that contain Aβ after 4 weeks rAAV2-Phe or rAAV2-IL1β injection. Data displayed as mean ± SEM, n = 5 animals, ***p < 0.0001, ****p < 0.00001.
c Representative images of Arg1+ or iNOS+ microglia containing 6E10 inside the lysosome (Lamp1). Scale bars represent 10 μm
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Discussion
Here we report that Arg1+ microglia appear to partici-
pate in Aβ plaque clearance during sustained IL-1β in-
flammation. These results provide a mechanism to
explain our previously published findings that sustained
neuroinflammation leads to plaque reduction [3, 4]. The
observation that an inflammatory stimulus results in an
anti-inflammatory or beneficial phenotype seems contra-
dictory at first. However, the concept of negative-
feedback mechanisms is well-established in inflamma-
tory states, which are kept in check via upregulation of
anti-inflammatory factors via multiple mechanisms [29].
Furthermore, the idea that IL-1β does not directly re-
duce Aβ is supported in a recent publication by Heneka
et al., where APP/PS1 mice were crossed to NLRP3(−/−)
mice that lack IL-1β production [30]. This mouse dem-
onstrated elevated alternatively activated microglia
markers, greater microglial Aβ phagocytosis, and re-
duced plaque load compared to control APP/PS1 mice.
These findings are very similar to ours, suggesting that
direct actions of IL-1β do not explain the reduction in
Aβ observed in our model. It is also unlikely that IL-1β
directly drives alternative activation of microglia to ex-
press Arg1 [31]. Our observations are consistent with a
model by which sustained neuroinflammation generated
Fig. 5 IL-4-producing cells are present in the CNS with sustained
IL-1β inflammation. a Representative images of GFP+ cells in the
hippocampus of IL-4 GFP reporter mice, 4 weeks after rAAV2-IL1β or
rAAV2-Phe injection. Scale bar represents 100 μm. b qRT-PCR analysis
of IL-4 mRNA levels for hippocampal lysates. Data was analyzed
using paired Student’s t test. n = 4 animals, mean ± SEM
shown, *p < 0.05
Fig. 6 IL-4 injection leads to Arg1+ cell induction and Aβ plaque
reduction. a Representative images of Arg1+ cells (green)
surrounding 6E10 Aβ plaques (red) 5 days after intrahippocampal
IL-4 injection (100 ng). Scale bar represents 100 μm. b Quantitative
dot plot analysis of the percent area occupied by 6E10 in the saline
vs. IL-4-injected sides of five mice. Data was analyzed using paired
Student’s t test, *p < 0.05
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by rAAV2-IL1β recruits cells capable of producing Th2
cytokines to the CNS in order to quell the inflammation
and mitigate possible damage. In addition, our experi-
ments suggest that endogenous brain cells may also lo-
cally produce IL-4 in the setting of sustained
neuroinflammation. One caveat to our approach is the
use of an IL-4 reporter mouse or qRT-PCR analysis,
which does not provide direct evidence of IL-4 protein
production. However, a recent publication from the la-
boratory of Jonathan Kipnis uses a different IL-4 re-
porter system that can identify bona fide IL-4 protein
producer cells [32]. They observed the infiltration of IL-
4-producing T cells after two different CNS injuries. Fur-
thermore, their findings implicate these IL-4-producing
T cells in neuroprotection. While the end points are
different, their results and ours both underscore an
Fig. 7 IL-4 signal blockade inhibits Arg1+ microglia induction and partially impairs Aβ plaque reduction. Representative images depict Arg1+
microglia (a, green) and 6E10 (b, red) 28 days post-injection and cannula implantation. Scale bar represents 100 μm. Quantification of Arg1+ cell
number (c), iNOS+ cell number (d), and 6E10 Aβ plaque area (e), in the hippocampus. Data was analyzed with Student’s t test. n = 7–8 animals;
mean ± SEM shown; **p < 0.005, ***p < 0.0001. f Correlation was determined by plotting the Arg1 cell count by plaque ratio for each animal. The
plaque ratio was generated by dividing the amount of plaque area in the inflamed hemisphere by the amount of plaque area in the control
hemisphere. This was performed on three hippocampal sections per mouse then averaged together. The higher the number, the more plaque is
present in the inflamed hippocampus. Each dot represents one animal. Black dots denote the control IgG while red dots denote mice that
received anti-IL-4Rα. r Pearson’s coefficient
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important protective mechanism for homeostasis in
CNS disease.
The induction and beneficial roles of alternatively acti-
vated microglia have been topics of debate for several
years. In the context of neuroinflammation, we observed
twice as many Arg1+ microglia containing Aβ than
iNOS+ microglia (Fig. 3). Although we have not directly
conducted Aβ phagocytosis assays with Arg1+ and
iNOS+ cells, our results are consistent with several
other studies indicating that inflammatory microglia
are poor phagocytes of Aβ [14, 16, 33]. There is some
evidence that inflammatory microglia can take up Aβ,
but cannot properly clear it [34]. This concept has
been coined “frustrated phagocytosis” and has been
implicated as a mechanism for plaque accumulation
in AD [35]. This idea can possibly explain the results
observed in Fig. 4b. Even though we observed iNOS+
cells containing Aβ in the control non-inflamed hemi-
sphere, Aβ plaque reduction was only seen when
Arg1+ cells were present. This is consistent with in
vitro findings that IL-4-treated microglia are poten-
tially more efficient phagocytes [33], as well as an in
vivo finding in which elevated Arg1 and reduced
iNOS mRNA correlated with greater Aβ microglial
phagocytosis and reduced amyloid plaque load [30].
The exact mechanism behind this is still unknown;
however, alternatively activated cells induced by IL-4
have a lower lysosomal pH, which results in greater
proteolytic capacity [36].
Support for the original idea of polarized microglial
phenotypes largely came from in vitro experiments in
peripheral macrophages using single cytokines and
examining expression of a limited set of genes. Recent
work has clearly demonstrated that microglia have
unique genetic differences from macrophages and that
the in vivo environment is more complex than revealed
by tissue culture [24, 37]. In efforts to better characterize
the microglial population in our experimental condi-
tions, we ran a multi-gene qRT-PCR array (Fig. 3). Ori-
ginally, we hoped to use the M1/M2abc classification
system [38, 39] to better understand potential functions
of these microglia. However, we observed a mixed
phenotype of cells that expressed both inflammatory and
anti-inflammatory markers, a finding consistent with
other observations in AD mouse models [39, 40]. For ex-
ample, proposed M2 markers such as Arg1 and YM1
were elevated, but we also observed increases in IL-1β
and TNFα. Furthermore, we found that other M2
markers such as Fizz1 and TREM2 were decreased. The
decrease in TREM2 was particularly surprising given re-
cent reports that TREM2 loss of function mutations are
a risk factor for AD [41]. However, some have argued
that loss of TREM2 results in amelioration of Aβ path-
ology [42]. Additional studies would be required to
determine whether changes in TREM2 expression are
related to the reduction of plaque that we see in our
model.
The mixed phenotype observed by mRNA profiling
could be explained due to sampling several different
populations of microglia within brain tissue. Indeed, im-
munofluorescent staining results shown in Fig. 4 suggest
the presence of both inflammatory and anti-
inflammatory microglia. However, it is possible that indi-
vidual cells still express a mixed phenotype. To explore
this fully, we would need to examine microglial cell
phenotype at the single-cell level. Interestingly, work
from the laboratory of Christine Hsieh suggests that
even if unique populations of Arg1+ macrophages are
sorted after traumatic brain injury, a mixed phenotype is
still observed [43]. This suggests the possibility that cells
with mixed phenotypic markers were present in our
model. Thus, we have elected to define this cell popula-
tion by Arg1+ expression rather than defining it as M1
or M2.
Due to the complexity and likely flux of microglial
phenotypes, it is difficult to prove that one microglia
subtype is involved in Aβ plaque clearance. However,
the work described here presents a possible mechan-
ism whereby Arg1+ microglia might participate in in
vivo Aβ clearance. This data is in agreement with
previously published reports using different AD
mouse models, which demonstrated an association be-
tween IL-4-induced Arg1+ microglia (via either AAV-
IL-4 or acute IL-4 injection) and plaque clearance
[15, 44]. This does not rule out other mechanisms of
Aβ clearance, as we did not see a complete inhibition
during antibody treatment. Furthermore, it will be im-
portant to consider the effect of IL-4 on other cell
types in the CNS. In particular, many other cell types,
including those we observe in the inflamed state
(Fig. 2), possess the IL-4Rα [45–49] and are therefore
potential targets of receptor blockade. Future experi-
ments will be necessary to determine the roles of other
cell types in promoting Aβ clearance. Nevertheless, from a
therapeutic perspective, it is promising that we associated
amyloid clearance with a microglial population marked by
Arg1 expression. Interestingly, the data from these studies
and several others like it have spurred clinical studies
[50, 51] aimed to switch inflammatory microglia to a
more beneficial phenotype. PPARγ agonists [52], bex-
arotene [53], and glatiramer acetate [54] are just a
few of the therapeutics currently being tested to in-
duce beneficial microglial phenotypes during disease;
many of these approaches impact at least some aspect
of the IL-4-signaling cascade [8]. Our observations
provide compelling evidence that IL-4-dependent
Arg1+ microglia are involved in Aβ plaque reduction.
This study helps to define one mechanism of microglia-
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dependent Aβ clearance; in particular, our approach utiliz-
ing an IL-4Rα antibody leaves the inflammatory response
intact, demonstrating that anti-inflammatory microglia are
necessary for Aβ clearance. Being able to tease glial phe-
notypes apart during in vivo neuroinflammation is an im-
portant step in understanding functions of unique cell
phenotypes that might be elicited by other approaches.
However, not all see beneficial outcomes with anti-
inflammatory cytokine treatment. Chakrabarty et al. re-
ported an opposite effect of IL-4 on AD [55], with sus-
tained AAV-IL-4 expression leading to increased plaque
accumulation. It is not clear why there are conflicting
outcomes, but different transgenic mice might underlie
the contradictory results as well as different approaches,
durations, and doses of IL-4 used. Furthermore, recent
reports indicate that IL-10 is detrimental in AD, with IL-
10−/− mice crossed to APP/PS1 mice showing reduced
Aβ plaque pathology [56]. This mechanism was attrib-
uted to an elevation in phagocytic ability of microglia.
Clearly, more work needs to be performed to better
understand the relationships between inflammatory and
anti-inflammatory responses, the plasticity of microglia,
and their roles in disease.
In conclusion, we observed Arg1+ microglia during
sustained IL-1β neuroinflammation. These cells appear
to arise from the recruitment of cells capable of produ-
cing Th2 cytokines, such as IL-4, that alternatively
activate a population of endogenous microglial cells,
presumably to maintain homeostasis. Interestingly, these
Arg1+ microglia appeared to be more adept at Aβ phago-
cytosis compared to inflammatory iNOS+ microglia, sug-
gesting that they may underlie our observations of plaque
clearance when IL-1β is overexpressed. Indeed, our data
showing that IL-4 alone was sufficient to mediate Arg1+
cell induction and reduced plaque load, combined with evi-
dence that blocking IL-4 signaling partially abrogated the
effects of IL-1β on Arg1+ cell induction and plaque clear-
ance, supports a model whereby Arg1+ cells participate in
plaque clearance in the setting of sustained neuroinflam-
mation. Future studies with in vivo imaging of the
interaction between these cells and Aβ deposits could be
performed to provide further evidence for this mechanism.
Additional file
Additional file 1: Figure S1. Bone marrow chimeric mice demonstrate
minimal overlap between peripheral donor RFP+ cells and Arg1+ cells.
Representative image depicting RFP+ donor cells (red) and Arg1+ cells
(green) 1 month after AAV-IL1β injection. Scale bar represents 50 μm.
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